Meta-analysis application to hERG safety evaluation in clinical trials

被引:0
|
作者
Zhao, Xutong [1 ]
Sun, Jing [1 ]
Huang, Dalong [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Biometr 6, Off Biostat, Silver Spring, MD 20993 USA
关键词
Concentration-QTc model; cardiac safety assessment; meta-analysis; safety margin; thorough QT study; THOROUGH QT/QTC; PROLONG; QTC;
D O I
10.1080/10543406.2024.2365972
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
One objective of meta-analysis, which synthesizes evidence across multiple studies, is to assess the consistency and investigate the heterogeneity across studies. In this project, we performed a meta-analysis on moxifloxacin (positive control in QT assessment studies) data to characterize the exposure-response relationship and determine the safety margin associated with 10-msec QTc effects for moxifloxacin based on 26 thorough QT studies submitted to the FDA. Multiple meta-analysis methods were used (including two novel methods) to evaluate the exposure-response relationship and estimate the critical concentration and the corresponding confidence interval of moxifloxacin associated with a 10-msec QTc effect based on the concentration-QTc models. These meta-analysis methods (aggregate data vs. individual participant data; fixed effect vs. random effect) were compared in terms of their precision and robustness. With the selected meta-analysis method, we demonstrated the homogeneity and heterogeneity of the moxifloxacin concentration-QTc relationship in studies. We also estimated the critical concentration of moxifloxacin that can be used to calculate the hERG safety margin of this drug.
引用
收藏
页码:343 / 355
页数:13
相关论文
共 50 条
  • [1] Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
    Monami, M.
    Genovese, S.
    Mannucci, E.
    DIABETES OBESITY & METABOLISM, 2013, 15 (10) : 938 - 953
  • [2] Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials
    Shi, Qian
    Sargent, Daniel J.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (02) : 102 - 111
  • [3] Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials
    Qian Shi
    Daniel J. Sargent
    International Journal of Clinical Oncology, 2009, 14 : 102 - 111
  • [4] The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials
    Bajtel, Akos
    Kiss, Tivadar
    Toth, Barbara
    Kiss, Szabolcs
    Hegyi, Peter
    Vorhendi, Nora
    Csupor-Loffler, Boglarka
    Gede, Noemi
    Hohmann, Judit
    Csupor, Dezso
    PHARMACEUTICALS, 2022, 15 (01)
  • [5] Meta-analysis in clinical trials revisited
    DerSimonian, Rebecca
    Laird, Nan
    CONTEMPORARY CLINICAL TRIALS, 2015, 45 : 139 - 145
  • [6] An Empirical Bayes Method for Multivariate Meta-analysis with an Application in Clinical Trials
    Chen, Yong
    Luo, Sheng
    Chu, Haitao
    Su, Xiao
    Nie, Lei
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 2014, 43 (16) : 3536 - 3551
  • [7] Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials
    Qiu, Sangsang
    Shen, Ye
    Pan, Hongqiu
    Wang, Jianming
    Zhang, Qun
    INFECTIOUS DISEASES, 2015, 47 (11) : 808 - 819
  • [8] The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
    Jin, Conghui
    Zhang, Xunlei
    Zhao, Kuiling
    Xu, Jun
    Zhao, Min
    Xu, Xiaohong
    ONCOTARGETS AND THERAPY, 2016, 9 : 1571 - 1578
  • [9] Cardiac safety profile of rosiglitazone A comprehensive meta-analysis of randomized clinical trials
    Mannucci, Edoardo
    Monami, Matteo
    Di Bari, Mauro
    Lamanna, Caterina
    Gori, Francesca
    Gensini, Gian Franco
    Marchionni, Niccolo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 143 (02) : 135 - 140
  • [10] The role of meta-analysis in cancer clinical trials
    Chikuma Hamada
    International Journal of Clinical Oncology, 2009, 14 : 90 - 94